



2016 Cancer Program Annual Report

J. Phillip Citta Regional Cancer Center
Community Medical Center
RWJBarnabas Health

A statistical report of cancer cases seen at RWJBarnabas Health - Community Medical Center (CMC) in 2016. This data is benchmarked against the National Cancer Data Base. Some of the graphical representations include a breakdown of cases by Age, Gender, Race, as well as more site specific data.

Messages from the Cancer Committee Chair

The J. Phillip Citta Regional Cancer Center at Community Medical Center has had a busy year in 2016. We celebrated the 5th anniversary of our New Jersey Cyberknife Radiosurgery Treatment Center and have seen exciting growth of this treatment option for a wider range of patients in our community. We achieved accreditation by the National Accreditation Program of Breast Centers (NAPBC) for our breast cancer program, which makes this cancer center the only facility in Ocean & Atlantic Counties with this level of review and accreditation. Applying for and achieving these accreditations is important as they represent a commitment to patient care quality and the availability of comprehensive diagnostic, treatment, and supportive care modalities. This reassures the patient's in our community that they have a full spectrum of cancer care available and that this care meets national benchmarks and standards.

Furthering this commitment to quality is a new relationship with Robert Wood Johnson Medical Center/Cancer Institute of New Jersey (CINJ), which is now led by newly appointed Director and Senior Vice President Dr. Steven Libutti. CINJ is a leader in cancer care in our state and we are proud to be a part of their system.

Thank you.

Rajesh Iyer, MD
Chairman, CMC Cancer Committee

J. Phillip Citta

Regional Cancer Center

- Designated by the Commission on Cancer (CoC) of the American College of Surgeons as a Community Hospital Comprehensive Cancer Program since 1986.
- Accredited Breast Center of Excellence from the National Accreditation Program of Breast Centers (NAPBC) – only hospital in Ocean and Atlantic Counties.

Cancer Committee Members

- **Rajesh Iyer, MD, Cancer Committee Chairman,**
Radiation Oncology
- **Stephen Kupferberg, MD, Vice Chairperson, Cancer
Committee, Cancer Liaison Physician, ENT**
- **Chirag Shah, MD, Medical Oncology/ PI Oncology
Research**
- **Jane Park, MD, Surgery**
- **Mohammad Hafiz, MD, Pathology /Cancer Conference
Coordinator**
- **Marianne Holler, DO, F.A.C.O.I., Home Health /
Hospice**
- **Robert Braun, MA, M.Ed.,RN,OCN, RT (T)(R), VP
Oncology Services**
- **Marley Nicolas, RN, MSN, Administrative Director
Cancer Services**
- **Jonathan Gapilango, RN, MSN, OCN, CCRP, NE-BC,
Director, Oncology Research & Oncology Data Center**
- **Lennette Gonzales, RN, MSHS,OCN, CCRP, Oncology
Research**

Cancer Committee Members (cont.)

- **Cheryl O'Blek, RN, BSN, OCN, QI Coordinator**
- **Jane Krong, RN, BSN, OCN, Inpatient Oncology Nursing**
- **Karen Purcell, BS, Community Outreach Coordinator**
- **Tracie Barberi-Matthews, MSW, LCSW, OSW-C, Psychosocial Services**
- **Kathe Wright, RN, MSN, RN-C, Breast Nurse Navigator**
- **Veronica Keough, BA, CTR, Cancer Registry Coordinator**
- **Kaitlin Kraft, MS GC, Genetic Counselor**
- **Veronica Gajda, RD, CSO, Nutrition Services**
- **Lynne Goldstein, PharmD, RPh, Pharmacy Services**
- **Ray Howard, Rehab Services**
- **Jean Flaherty, Marketing**
- **Melissa White, American Cancer Society Navigator**
- **Kimberly Gittines, Health Systems Manager, ACS**

Cancer Committee

Alternate Members

- **David D'Ambrosio, MD, Radiation Oncology**
- **Bruce Peters, DO, ENT**
- **Gurpreet Lamba, MD, Medical Oncology**
- **Apurv Agrawal, MD, Medical Oncology**
- **Tarun Bhandari, MD, Surgery**
- **Christina Dambroski, RN, OCN, QI Coordinator**
- **Anne, McGarry, MSW, Community Outreach**
- **Marianne Brown, RN, MSN, OCN, Out Patient Oncology Nursing**
- **Dorothy Moloney, RN, Home Health / Hospice**
- **Debbie Feeney, BA, CTR, Cancer Registry**

CLASS OF CASE




Figure 1

RACE




Figure 2

STATISTICAL SUMMARY OF CANCER CASES AT CMC

PATIENT DEMOGRAPHICS

Data from the American Cancer Society's *Facts and Figures for 2016* estimated that there will be over 1,685,210 new cancer cases in 2016, 49,750 will be diagnosed in New Jersey.

In 2016, there were 1441 new cancer cases accessioned at Community Medical Center (CMC).

Of the 1441 cases, the non-analytic cases include 181 that were seen for recurrent or progressive disease (Classes 30-38) and 22 cases that were pathology review cases (Class 43). The following statistical report is based on the remaining 1235 analytic cases, of which, 100 were diagnosed at CMC and went elsewhere for treatment (Class 00), 750 were diagnosed and treated at CMC (Classes 10-14) and 388 were diagnosed at another facility and referred to CMC for treatment (Classes 20-22). **Figure 1** represents a breakdown by class of case.


Medicare was the primary insurance coverage for 68% of patients followed by Managed Care at 22% and 4% Medicaid.

Gender distribution revealed 56% females and 44% males. Race distribution included: White: 96%, Black: 2%, and other or unspecified race at <1%. **Figure 2** is a representation by gender and race.

SITE DISTRIBUTION

Figure 3 summarizes the top five analytical primary sites for 2016 which include lung, breast, melanoma, prostate and colon.

TOP 5 SITES



The J. Phillip Citta
Regional Cancer Center
and Infusion Suite



ALL SITES Primary Site	Total (%)	Sex		Class of Case		Vital Status		Stage Distribution - Analytic Cases Only						
		M	F	Anal	NA	Alive	Exp	Stg 0	Stg I	Stg II	Stg III	Stg IV	88	Unk
ORAL CAVITY & PHARYNX	35 (2.4%)	27	8	33	2	33	2	0	6	3	4	15	0	5
Lip	1 (0.1%)	1	0	1	0	1	0	0	1	0	0	0	0	0
Tongue	14 (1.0%)	9	5	13	1	13	1	0	2	0	0	7	0	4
Salivary Glands	2 (0.1%)	1	1	2	0	2	0	0	0	1	1	0	0	0
Floor of Mouth	3 (0.2%)	3	0	3	0	3	0	0	1	0	1	1	0	0
Gum & Other Mouth	4 (0.3%)	3	1	3	1	4	0	0	2	0	0	1	0	0
Nasopharynx	2 (0.1%)	2	0	2	0	1	1	0	0	0	0	1	0	1
Tonsil	6 (0.4%)	5	1	6	0	6	0	0	0	1	2	3	0	0
Oropharynx	2 (0.1%)	2	0	2	0	2	0	0	0	0	0	2	0	0
Hypopharynx	1 (0.1%)	1	0	1	0	1	0	0	0	1	0	0	0	0
DIGESTIVE SYSTEM	241 (16.7%)	135	106	212	29	170	71	5	42	56	41	49	4	15
Esophagus	26 (1.8%)	22	4	20	6	12	14	0	2	5	6	3	0	4
Stomach	11 (0.8%)	7	4	10	1	8	3	0	2	2	0	4	0	2
Small Intestine	2 (0.1%)	1	1	2	0	0	2	0	0	0	0	1	0	1
Colon Excluding Rectum	87 (6.0%)	44	43	80	7	69	18	3	17	26	17	16	1	0
Cecum	15	4	11	14	1	13	2	1	3	3	5	2	0	0
Appendix	1	0	1	1	0	1	0	0	0	0	0	0	1	0
Ascending Colon	28	15	13	27	1	21	7	0	6	13	6	2	0	0
Hepatic Flexure	2	1	1	2	0	2	0	0	0	1	0	1	0	0
Transverse Colon	9	6	3	9	0	9	0	0	3	3	3	0	0	0
Descending Colon	6	5	1	5	1	4	2	0	3	1	1	0	0	0
Sigmoid Colon	13	6	7	13	0	9	4	1	2	4	2	4	0	0
Large Intestine, NOS	13	7	6	9	4	10	3	1	0	1	0	7	0	0
Rectum & Rectosigmoid	49 (3.4%)	25	24	44	5	43	6	1	6	14	12	6	1	4
Rectosigmoid Junction	21	6	15	20	1	19	2	1	3	8	4	4	0	0
Rectum	28	19	9	24	4	24	4	0	3	6	8	2	1	4
Anus, Anal Canal & Anorectum	5 (0.3%)	3	2	5	0	4	1	0	3	2	0	0	0	0
Liver & Intrahepatic Bile Duct	19 (1.3%)	12	7	15	4	13	6	0	6	2	2	1	1	3
Liver	16	10	6	14	2	11	5	0	6	2	2	1	0	3
Intrahepatic Bile Duct	3	2	1	1	2	2	1	0	0	0	0	0	1	0
Gallbladder	3 (0.2%)	0	3	3	0	2	1	1	1	0	0	1	0	0
Other Biliary	1 (0.1%)	0	1	1	0	0	1	0	1	0	0	0	0	0
Pancreas	36 (2.5%)	21	15	30	6	17	19	0	4	5	3	17	0	1
Retroperitoneum	1 (0.1%)	0	1	1	0	1	0	0	0	0	1	0	0	0
Peritoneum, Omentum & Mesentery	1 (0.1%)	0	1	1	0	1	0	0	0	0	0	0	1	0
RESPIRATORY SYSTEM	280 (19.4%)	125	155	249	31	186	94	4	71	22	47	88	2	15
Larynx	13 (0.9%)	11	2	10	3	11	2	2	2	2	1	2	0	1
Lung & Bronchus	267 (18.5%)	114	153	239	28	175	92	2	69	20	46	86	2	14
SOFT TISSUE	12 (0.8%)	6	6	9	3	9	3	0	0	5	1	0	1	2
Soft Tissue (including Heart)	12 (0.8%)	6	6	9	3	9	3	0	0	5	1	0	1	2
SKIN EXCLUDING BASAL & SQUAMOUS CELL	110 (7.6%)	75	35	89	21	101	9	41	25	13	4	2	0	4
Melanoma -- Skin	107 (7.4%)	72	35	87	20	98	9	41	24	12	4	2	0	4
Other Non-Epithelial Skin	3 (0.2%)	3	0	2	1	3	0	0	1	1	0	0	0	0
BREAST	241 (16.7%)	239	203	38	231	10	29	92	48	18	10	1	5	
Breast	241 (16.7%)	239	203	38	231	10	29	92	48	18	10	1	5	
FEMALE GENITAL SYSTEM	111 (7.7%)	0	111	101	10	96	15	2	52	6	20	11	5	5
Cervix Uteri	13 (0.9%)	0	13	12	1	8	5	0	4	1	4	3	0	0
Corpus & Uterus, NOS	64 (4.4%)	0	64	62	2	60	4	1	42	2	8	5	3	1
Corpus Uteri	60	0	60	59	1	58	2	1	41	2	8	3	3	1
Uterus, NOS	4	0	4	3	1	2	2	0	1	0	0	2	0	0
Ovary	21 (1.5%)	0	21	18	3	18	3	0	3	1	8	3	1	2
Vagina	1 (0.1%)	0	1	0	1	1	0	0	0	0	0	0	0	0
Vulva	11 (0.8%)	0	11	8	3	8	3	1	3	2	0	0	0	2
Other Female Genital Organs	1 (0.1%)	0	1	1	0	1	0	0	0	0	0	0	1	0
MALE GENITAL SYSTEM	96 (6.7%)	96	0	73	23	90	6	0	16	45	4	5	0	3
Prostate	92 (6.4%)	92	0	70	22	86	6	0	16	44	3	5	0	2
Testis	3 (0.2%)	3	0	3	0	3	0	0	0	1	1	0	0	1
Penis	1 (0.1%)	1	0	0	1	1	0	0	0	0	0	0	0	0
URINARY SYSTEM	88 (6.1%)	66	22	74	14	72	16	29	13	15	1	12	0	4
Urinary Bladder	67 (4.6%)	50	17	58	9	56	11	25	12	13	0	6	0	2
Kidney & Renal Pelvis	19 (1.3%)	15	4	14	5	14	5	2	1	2	1	6	0	2
Ureter	2 (0.1%)	1	1	2	0	2	0	2	0	0	0	0	0	0
BRAIN & OTHER NERVOUS SYSTEMS	20 (1.4%)	9	11	17	3	19	1	0	0	0	0	0	17	0
Brain	17 (1.2%)	9	8	15	2	16	1	0	0	0	0	0	15	0
Cranial Nerves Other Nervous System	3 (0.2%)	0	3	2	1	3	0	0	0	0	0	0	2	0
ENDOCRINE SYSTEM	48 (3.3%)	15	33	39	9	47	1	0	18	3	1	1	2	14
Thyroid	43 (3.0%)	12	31	36	7	43	0	0	18	3	1	0	0	14
Other Endocrine including Thyroid	5 (0.3%)	3	2	3	2	4	1	0	0	0	0	1	2	0

ALL SITES Primary Site	Total (%)	Sex		Class of Case		Vital Status		Stage Distribution - Analytic Cases Only						
		M	F	Analy	NA	Alive	Exp	Stg 0	Stg I	Stg II	Stg III	Stg IV	88	Unk
LYMPHOMA	54 (3.7%)	29	25	45	9	48	6	0	17	7	6	5	1	9
Hodgkin Lymphoma	4 (0.3%)	2	2	3	1	3	1	0	2	0	0	0	0	1
Non-Hodgkin Lymphoma	50 (3.5%)	27	23	42	8	45	5	0	15	7	6	5	1	8
NHL - Nodal	33	13	20	31	2	29	4	0	12	3	4	4	0	8
NHL - Extranodal	17	14	3	11	6	16	1	0	3	4	2	1	1	0
MYELOMA	17 (1.2%)	8	9	14	3	11	6	0	0	0	0	0	14	0
Myeloma	17 (1.2%)	8	9	14	3	11	6	0	0	0	0	0	14	0
LEUKEMIA	28 (1.9%)	18	10	26	2	15	13	0	0	0	0	0	26	0
Lymphocytic Leukemia	10 (0.7%)	5	5	10	0	5	5	0	0	0	0	0	10	0
Acute Lymphocytic Leukemia	1	1	0	1	0	1	0	0	0	0	0	0	1	0
Chronic Lymphocytic Leukemia	9	4	5	9	0	4	5	0	0	0	0	0	9	0
Myeloid & Monocytic Leukemia	18 (1.2%)	13	5	16	2	10	8	0	0	0	0	0	16	0
Acute Myeloid Leukemia	15	11	4	15	0	7	8	0	0	0	0	0	15	0
Chronic Myeloid Leukemia	3	2	1	1	2	3	0	0	0	0	0	0	1	0
MESOTHELIOMA	11 (0.8%)	7	4	10	1	8	3	0	6	0	0	0	3	1
Mesothelioma	11 (0.8%)	7	4	10	1	8	3	0	6	0	0	0	3	1
MISCELLANEOUS	48 (3.3%)	18	30	45	3	31	17	0	0	0	0	0	45	0
Miscellaneous	48 (3.3%)	18	30	45	3	31	17	0	0	0	0	0	45	0

Table 1 (cont.)

Table 2 & 3 summarize five primary sites for 2016 by gender and compares CMC’s actual cases and the estimated figures from the American Cancer Society (ACS).

MALES		
	CMC	ACS
Prostate	12%	21%
Lung	21%	14%
Colon & Rectum	12%	8%
Bladder	9%	7%
Melanoma	11%	6%

Table 2

FEMALES		
	CMC	ACS
Breast	30%	29%
Lung	17%	13%
Colon & Rectum	10%	8%
Uterus	7%	7%
Thyroid	5%	6%

Table 3

Figure 4 depicts age distribution in comparison with the National Cancer Data Base (NCDB) which is 2014. NCDB data includes cases of all Commission on Cancer Approved Cancer Program hospitals. Twenty-eight percent (28%) of patients at CMC were diagnosed between the ages of 70-79 compared to 23% at NCDB.

Age at Diagnosis





Figure 4



Percent Unknown

- Lung = 11.68%
- Breast = 7.85%
- Melanoma = 16.81%
- Colon = 5.61%
- Prostate = 7.61%

Figure 5

Figure 6 depicts patient’s county at diagnosis. Ninety-nine percent (99%) of CMC new patients in 2016 resided in Ocean County. One percent (1%) resided in other counties/states.




Figure 6



3rd Annual Survivorship Celebration



Community Partners



HEALTHSOUTH.
Rehabilitation Hospital of Toms River
BUILDING A BETTER TOMORROW

[LEARN MORE](#)

